Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VTRS Stock Forecast 2026-2027
$16.32
Current Price
$19.01B
Market Cap
Buy 5
Hold 4
Sell 1
Wall St Analyst Ratings
Distance to VTRS Price Targets
+40.9%
To High Target of $23.00
+7.2%
To Median Target of $17.50
-26.5%
To Low Target of $12.00
VTRS Price Momentum
+0.7%
1 Week Change
-1.0%
1 Month Change
+81.5%
1 Year Change
+31.1%
Year-to-Date Change
-6.9%
From 52W High of $17.53
+89.1%
From 52W Low of $8.63
📊 TOP ANALYST CALLS
Did VTRS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Viatris is one of their latest high-conviction picks.
Latest VTRS Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, VTRS has a neutral consensus with a median price target of $17.50 (ranging from $12.00 to $23.00). The overall analyst rating is Buy (7.6/10). Currently trading at $16.32, the median forecast implies a 7.2% upside. This outlook is supported by 5 Buy, 4 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VTRS Analyst Ratings
5
Buy
4
Hold
1
Sell
VTRS Price Target Range
Low
$12.00
Average
$17.50
High
$23.00
Current: $16.32
Latest VTRS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VTRS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 19, 2026 | Barclays | Glen Santangelo | Overweight | Maintains | $22.00 |
| May 8, 2026 | JP Morgan | Neutral | Maintains | $N/A | |
| May 8, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| Mar 24, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Jan 28, 2026 | Piper Sandler | Neutral | Maintains | $N/A | |
| Jan 16, 2026 | Argus Research | Buy | Upgrade | $N/A | |
| Dec 9, 2025 | Barclays | Overweight | Initiates | $N/A | |
| Oct 15, 2025 | Truist Securities | Buy | Initiates | $N/A | |
| Jun 6, 2025 | Goldman Sachs | Neutral | Initiates | $N/A | |
| Mar 7, 2025 | Jefferies | Buy | Maintains | $N/A | |
| Mar 5, 2025 | Piper Sandler | Neutral | Reiterates | $N/A | |
| Feb 28, 2025 | Barclays | Underweight | Maintains | $N/A | |
| Feb 28, 2025 | B of A Securities | Underperform | Maintains | $N/A | |
| Dec 6, 2024 | Piper Sandler | Neutral | Reiterates | $N/A | |
| Nov 8, 2024 | Barclays | Underweight | Maintains | $N/A | |
| Jul 19, 2024 | Jefferies | Glen Santangelo | Buy | Reinstates | $15.00 |
| Mar 28, 2024 | Piper Sandler | Neutral | Reiterates | $N/A | |
| Nov 22, 2023 | Piper Sandler | Neutral | Maintains | $N/A | |
| Oct 23, 2023 | B of A Securities | Underperform | Downgrade | $N/A | |
| Jun 23, 2023 | Barclays | Underweight | Downgrade | $N/A |
Viatris Inc. (VTRS) Competitors
The following stocks are similar to Viatris based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Viatris Inc. (VTRS) Financial Data
Viatris Inc. has a market capitalization of $19.01B with a P/E ratio of 235.8x. The company generates $14.56B in trailing twelve-month revenue with a -2.0% profit margin.
Revenue growth is +8.1% quarter-over-quarter, while maintaining an operating margin of +6.8% and return on equity of -2.0%.
Valuation Metrics
Market Cap
$19.01B
Enterprise Value
$31.22B
P/E Ratio
235.8x
PEG Ratio
-2.2x
Price/Sales
1.3x
Growth & Margins
Revenue Growth (YoY)
+8.1%
Gross Margin
+32.9%
Operating Margin
+6.8%
Net Margin
-2.0%
EPS Growth
+8.1%
Financial Health
Cash/Price Ratio
+12.6%
Current Ratio
1.6x
Debt/Equity
99.7x
ROE
-2.0%
ROA
+2.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Viatris Inc. (VTRS) Business Model
About Viatris Inc.
What They Do
Global healthcare company delivering quality medicines.
Business Model
The company generates revenue by offering a diverse portfolio of generic medications, complex products, biosimilars, and established brand-name drugs. It operates in various therapeutic areas and utilizes extensive manufacturing and scientific expertise to meet global health demands.
Additional Information
With over 1,400 approved molecules, Viatris has a significant presence in more than 165 countries and aims to enhance health access worldwide. The company's strategic locations include manufacturing sites in the U.S., China, and India, allowing it to effectively serve a broad range of healthcare needs.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
30,000
CEO
Mr. Scott Andrew Smith Ph.D.
Country
United States
IPO Year
1980
Website
www.viatris.comViatris Inc. (VTRS) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Is Amneal a Buy Before Rytary Generic Erosion?
AMRX faces Rytary generic pressure in 2026, but growth in generics, injectables, biosimilars, and higher profitability targets could support its outlook.
Jun 09, 2026
By Kanishka Das
Analyst Blog Plus
3 Generic Drug Stocks to Watch as New Growth Drivers Emerge
Sandoz, Teva and Viatris target biosimilars, complex generics and specialty drugs as new growth drivers reshape the Medical - Generic Drugs industry.
Jun 05, 2026
By Zacks Equity Research
Industry Outlook
Latest News
Quick Summary
Sandoz, Teva, and Viatris are focusing on biosimilars, complex generics, and specialty drugs to drive growth in the Medical - Generic Drugs industry.
Why It Matters
Sandoz, Teva, and Viatris shifting focus to biosimilars and specialty drugs signals industry evolution, potentially enhancing market competitiveness and growth opportunities for these companies.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Zacks Style Scores can help investors identify strong stocks that may outperform the market for their investment portfolio.
Why It Matters
Zacks Style Scores can guide investors in selecting high-performing stocks, potentially enhancing portfolio returns and aiding in achieving market outperformance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
The FDA has accepted Viatris Inc.'s NDA for fast-acting meloxicam (MR-107A-02) for acute pain treatment, with a PDUFA goal date set for December 27, 2026.
Why It Matters
The FDA's acceptance of Viatris' NDA for a new pain treatment indicates potential revenue growth and market expansion, influencing stock performance and investor interest ahead of the decision date.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Zacks Style Scores can guide investors in selecting strong, market-beating stocks for their portfolios.
Why It Matters
The Zacks Style Scores provide a systematic method to identify high-potential stocks, aiding investors in constructing portfolios that outperform the market.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
VTRS' NDA for fast-acting meloxicam, a non-opioid acute pain therapy, is under FDA review, with a decision anticipated by December 27, 2026.
Why It Matters
VTRS' NDA for meloxicam could lead to market approval for a non-opioid pain therapy, potentially boosting sales and enhancing its competitive position in the pharmaceutical sector.
Source: Zacks Investment Research
Market Sentiment:
Negative
Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
1 month ago
Quick Summary
Viatris Inc. (VTRS) presented at the Bank of America Global Healthcare Conference, discussing its strategic initiatives and financial outlook for 2026.
Why It Matters
Viatris' presentation at a major healthcare conference could signal key strategic insights, potential growth plans, and market positioning, impacting investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About VTRS Stock
What is Viatris Inc.'s (VTRS) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Viatris Inc. (VTRS) has a median price target of $17.50. The highest price target is $23.00 and the lowest is $12.00.
Is VTRS stock a good investment in 2026?
According to current analyst ratings, VTRS has 5 Buy ratings, 4 Hold ratings, and 1 Sell ratings. The stock is currently trading at $16.32. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VTRS stock?
Wall Street analysts predict VTRS stock could reach $17.50 in the next 12 months. This represents a 7.2% increase from the current price of $16.32. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Viatris Inc.'s business model?
The company generates revenue by offering a diverse portfolio of generic medications, complex products, biosimilars, and established brand-name drugs. It operates in various therapeutic areas and utilizes extensive manufacturing and scientific expertise to meet global health demands.
What is the highest forecasted price for VTRS Viatris Inc.?
The highest price target for VTRS is $23.00 from at , which represents a 40.9% increase from the current price of $16.32.
What is the lowest forecasted price for VTRS Viatris Inc.?
The lowest price target for VTRS is $12.00 from at , which represents a -26.5% decrease from the current price of $16.32.
What is the overall VTRS consensus from analysts for Viatris Inc.?
The overall analyst consensus for VTRS is neutral. Out of 2 Wall Street analysts, 5 rate it as Buy, 4 as Hold, and 1 as Sell, with a median price target of $17.50.
How accurate are VTRS stock price projections?
Stock price projections, including those for Viatris Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 8:55 AM UTC